Dimensional Fund Advisors LP increased its position in shares of MacroGenics Inc (NASDAQ:MGNX) by 56.9% during the 3rd quarter, Holdings Channel reports. The fund owned 283,517 shares of the biopharmaceutical company’s stock after acquiring an additional 102,778 shares during the quarter. Dimensional Fund Advisors LP’s holdings in MacroGenics were worth $5,239,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its position in shares of MacroGenics by 13.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 168,988 shares of the biopharmaceutical company’s stock valued at $3,123,000 after acquiring an additional 20,196 shares during the last quarter. Wells Fargo & Company MN raised its holdings in MacroGenics by 11.5% in the 3rd quarter. Wells Fargo & Company MN now owns 27,714 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 2,862 shares during the period. Citadel Advisors LLC raised its holdings in MacroGenics by 55.3% in the 3rd quarter. Citadel Advisors LLC now owns 85,927 shares of the biopharmaceutical company’s stock valued at $1,588,000 after buying an additional 30,594 shares during the period. Sphera Funds Management LTD. raised its holdings in MacroGenics by 157.0% in the 3rd quarter. Sphera Funds Management LTD. now owns 208,700 shares of the biopharmaceutical company’s stock valued at $3,857,000 after buying an additional 127,500 shares during the period. Finally, Hood River Capital Management LLC raised its holdings in MacroGenics by 2.2% in the 3rd quarter. Hood River Capital Management LLC now owns 588,799 shares of the biopharmaceutical company’s stock valued at $10,881,000 after buying an additional 12,606 shares during the period. 86.03% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MacroGenics Inc (MGNX) opened at $21.86 on Friday. The stock has a market cap of $787.65, a PE ratio of -4.87 and a beta of 2.79. MacroGenics Inc has a one year low of $14.36 and a one year high of $23.90.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.97) earnings per share. analysts expect that MacroGenics Inc will post -0.7 EPS for the current fiscal year.

Several brokerages recently issued reports on MGNX. BidaskClub lowered shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Zacks Investment Research lowered shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Cowen restated a “buy” rating on shares of MacroGenics in a report on Wednesday, January 24th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Finally, BTIG Research restated a “buy” rating and issued a $28.00 price objective on shares of MacroGenics in a report on Tuesday, January 23rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $30.60.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Eric Blasius Risser sold 3,000 shares of the business’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the sale, the senior vice president now owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Insiders have sold 13,000 shares of company stock worth $267,500 over the last quarter. Insiders own 8.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Dimensional Fund Advisors LP Purchases 102,778 Shares of MacroGenics Inc (MGNX)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/04/dimensional-fund-advisors-lp-purchases-102778-shares-of-macrogenics-inc-mgnx.html.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.